科研之友
微信
新浪微博
Facebook
分享链接
摘要
Background This therapeutic drug monitoring (TDM) study aimed to determine the role of olanzapine (OLZ) and N-desmethyl-OLZ (DMO) levels in the therapeutic efficacy of OLZ in patients with schizophrenia. Method Plasma concentrations of OLZ (C-OLZ) and DMO (C-DMO) in schizophrenic patients 12 hours post-dose were assessed. The correlations of C-OLZ and C-DMO with the various scores of the Positive and Negative Syndrome Scale (PANSS) were evaluated. A receiver operating characteristic curve (ROC) was utilized to identify the threshold C-OLZ and C-OLZ/C-DMO ratio for maintenance of satisfactory efficacy. Results A total of 151 samples from patients with schizophrenia were analyzed for individual C-OLZ and C-DMO levels. The mean C-OLZ and C-DMO levels were 37.0 +/- 25.6 and 6.9 +/- 4.7 ng/mL, respectively, and C-OLZ was similar to 50% higher in female or nonsmokers (p<0.01). In all patients, the daily dose of OLZ was positively correlated with C-OLZ and C-DMO. Linear relationships between C-OLZ and OLZ dose were observed in both nonsmokers and smokers (r(s) = 0.306, 0.426, p<0.01), although C-DMO was only correlated with OLZ dose in smokers (r(s) = 0.485, p<0.01) and not nonsmokers. In all patients, C-OLZ was marginally negatively correlated with the total PANSS score. The total PANSS score was significantly negatively correlated with the C-OLZ/C-DMO ratio (p<0.005), except in smokers. The ROC analysis identified a C-OLZ/C-DMO ratio >= 2.99 or C-OLZ >= 22.77 ng/mL as a predictor of maintenance of an at least mildly ill status (PANSS score <= 58) of schizophrenia in all patients. Conclusions A significantly negative correlation between the steady-state C-OLZ/C-DMO ratio and total PANSS score was observed in Taiwanese schizophrenic patients. TDM of both OLZ and DMO levels could assist clinical practice when individualizing OLZ dosage adjustments for patients with schizophrenia.
- 出版日期2016-2-5
